References

Long-term outcomes after treatment with clofarabine ± fludarabine with once-daily intravenous busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and myelodysplastic syndrome

10.1016/j.bbmt.2016.06.023 · 2016 · External reference

The synergistic cytotoxicity of clofarabine, fludarabine and busulfan in AML cells involves ATM pathway activation and chromatin remodeling

10.1016/j.bcp.2010.09.027 · 2011 · External reference

Synergistic cytotoxicity of the DNA alkylating agent busulfan, nucleoside analogs and suberoylanilide hydroxamic acid in lymphoma cell lines

10.3109/10428194.2011.634043 · 2012 · External reference

Total body irradiation or chemotherapy conditioning in childhood ALL: a multinational, randomized, noninferiority phase III study

10.1200/jco.20.02529 · 2021 · External reference

The impact of severe late-effects after 12 Gy fractionated total body irradiation and allogeneic stem cell transplantation for childhood leukemia (1988-2010)

10.1080/08880018.2019.1591549 · 2019 · External reference

Clofarabine-fludarabine-busulfan in HCT for pediatric leukemia: an effective, low toxicity, TBI-free conditioning regimen

10.1182/bloodadvances.2021005224 · 2022 · External reference

Association of busulfan exposure with survival and toxicity after haemopoietic cell transplantation in children and young adults: a multicentre, retrospective cohort analysis

10.1016/s2352-3026(16)30114-4 · 2016 · External reference

Fludarabine with pharmacokinetically guided IV busulfan is superior to fixed-dose delivery in pretransplant conditioning of AML/MDS patients

10.1038/bmt.2016.322 · 2017 · External reference

Fludarabine exposure in the conditioning prior to allogeneic hematopoietic cell transplantation predicts outcomes

10.1182/bloodadvances.2018029421 · 2019 · External reference

Pharmacokinetics and model-based dosing to optimize fludarabine therapy in pediatric hematopoietic cell transplant recipients

10.1016/j.bbmt.2017.06.021 · 2017 · External reference

Excellent T-cell reconstitution and survival depend on low ATG exposure after pediatric cord blood transplantation

10.1182/blood-2016-06-721936 · 2016 · External reference

Individualised dosing of anti-thymocyte globulin in paediatric unrelated allogeneic haematopoietic stem-cell transplantation (PARACHUTE): a single-arm, phase 2 clinical trial

10.1016/s2352-3026(21)00375-6 · 2022 · External reference

Population pharmacokinetics of clofarabine for allogeneic hematopoietic cell transplantation in pediatric patients

10.1111/bcp.14738 · 2021 · External reference

Population pharmacokinetics of clofarabine as part of pretransplantation conditioning in pediatric subjects before hematopoietic cell transplantation

10.1016/j.bbmt.2019.04.017 · 2019 · External reference

Population pharmacokinetic modeling of Thymoglobulin® in children receiving allogeneic-hematopoietic cell transplantation: towards improved survival through individualized dosing

10.1007/s40262-014-0214-6 · 2015 · External reference

Association between anti-thymocyte globulin exposure and CD4+ immune reconstitution in paediatric haemopoietic cell transplantation: a multicentre, retrospective pharmacodynamic cohort analysis

10.1016/s2352-3026(15)00045-9 · 2015 · External reference

Simultaneous quantification of busulfan, clofarabine and F-ARA-A using isotope labelled standards and standard addition in plasma by LC–MS/MS for exposure monitoring in hematopoietic cell transplantation conditioning

10.1016/j.jchromb.2017.04.025 · 2017 · External reference

Population pharmacokinetics of fludarabine in children and adults during conditioning prior to allogeneic hematopoietic cell transplantation

10.1007/s40262-018-0715-9 · 2019 · External reference

Immune reconstitution kinetics as an early predictor for mortality using various hematopoietic stem cell sources in children

10.1016/j.bbmt.2012.10.010 · 2013 · External reference

Prospective open-label phase II trial of individualized anti-thymocyte globulin for improved T-cell reconstitution after pediatric allogeneic hematopoietic cell transplantation: the parachute-study

10.1016/j.bbmt.2019.12.577 · 2020 · External reference

Impact of conditioning regimen on outcomes for children with acute myeloid leukemia undergoing transplantation in first complete remission. An analysis on behalf of the Pediatric Disease Working Party of the European Group for Blood and Marrow Transplanta

10.1016/j.bbmt.2016.11.022 · 2017 · External reference

Impact on long-term OS of conditioning regimen in allogeneic BMT for children with AML in first CR: TBI+CY versus BU+CY: a report from the Société Française de Greffe de Moelle et de Thérapie Cellulaire

10.1038/bmt.2013.185 · 2014 · External reference

Hematopoietic cell transplant in pediatric acute myeloid leukemia after similar upfront therapy; a comparison of conditioning regimens

10.1038/s41409-020-01201-w · 2021 · External reference

Fifty years of melphalan use in hematopoietic stem cell transplantation

10.1016/j.bbmt.2012.08.011 · 2013 · External reference